Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Antibody offerings
January 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—The 11th Annual Protein & Antibody Engineering Summit, held late last year, saw Abzena showcase its Discovery and Developability Services. The company’s Discovery Service uses murine immunization to generate antibodies with high affinity and desired functional properties, an offering that is integrated with full Developability Services to evaluate characteristics such as specificity, functionality, safety and manufacturability to increase the chances of clinical success.
 
Dr. Campbell Bunce, chief scientific officer at Abzena, said: “The development of biologics takes time, is expensive and subject to safety, functionality, stability and scalability liabilities. Having worked with hundreds of drug candidates, Abzena’s Discovery and Developability Services offer a defined approach that applies our expertise to guide the discovery and selection of the best drug candidates and reduce the risks that can significantly impact the time and cost typically associated with biopharmaceutical R&D.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.